Pfizer Inc. (NYSE: PFE) is one of the 13 Best Large Cap Stocks to Buy Right Now. On July 10, Pfizer Inc. (NYSE:PFE) shared ...

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

We view Pfizer’s dividends and share repurchase levels as reasonable. Pfizer has generally targeted close to a 50% payout in dividends as a percentage of normalized earnings, which seems about right ...

The news sparked a larger conversation about what exactly the best practices are to screen for prostate cancer. Turns out, it’s more complicated than it might seem. Host Ira Flatow is joined by ...

If you have an opening in your portfolio for a great stock with solid growth potential and perhaps even a respectable dividend yield, you would do well to give Pfizer (NYSE: PFE) some serious ...

Pfizer appears to be a very promising stock to buy if you're looking for income. That 7.3% dividend yield is terrific, and even if it gets slashed, it will likely still be substantial.

Astellas Pharma (ALPMY) and Pfizer (PFE) announced longer-term follow-up results from an open-label extension of the Phase 3 ARCHES study, reporting a five-year follow up of overall survival, or ...

Unpacking Pfizer’s 7.5% Promise Pfizer's commitment to returning capital to shareholders is evident in its current annual dividend of $1.72 per share.

Pfizer (NYSE:PFE) recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 clinical study of the innovative MesoC2 drug at the ASCO Annual Meeting ...